A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors
Clinical trial NCT05627063 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05627063
- Sponsor
- Abbisko Therapeutics Co, Ltd
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-06-26
- Primary completion
- 2026-03-15
- Enrollment
- 169
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.